№ files_lp_3_process_9_13442
File format: docx Character count: 8146 File size: 191 KB
Scientific review article synthesizing clinical, surgical, imaging, and molecular evidence on the multidisciplinary management of primary malignant bone sarcomas, with emphasis on therapeutic strategies and emerging biomarkers between 2015 and 2025.
Year of publication: 2025
Receipt of originals: 10/27/2025
Acceptance for publication: 11/27/2025
DOI: https://doi.org/10.56238/isevjhv4n6-002
Authors: Fernanda Cristina Galerani Gualtieri Parpinelli; Augustin Malzac; Henrique Lucas Codognoto; Cristina Jardelino de Lima; Guilherme Banck; Diogo Melo Mendo
Type of document: Narrative literature review
Field: Oncology; Orthopedic Oncology
Subject: Multidisciplinary management of osteosarcoma, chondrosarcoma, and Ewing sarcoma
Population focus: Pediatric and young patients with primary malignant bone tumors
Study period covered: 2015–2025
Databases consulted: PubMed; Scopus; Cochrane
Therapeutic approaches discussed: Surgical resection (R0 margins); Neoadjuvant and adjuvant chemotherapy (MAP; VAC/IE); Radiotherapy; Proton therapy; Immune checkpoint inhibitors; CAR-T cell therapy
Molecular aspects: EWS-FLI1 translocation; IDH1/IDH2 mutations; Circulating tumor DNA (ctDNA)
Imaging modalities: MRI; CT; PET-CT
Keywords: Osteosarcoma; Chondrosarcoma; Ewing Sarcoma; Targeted Therapy; EWS-FLI1; Biomarkers; Immunotherapy
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Preclinical Characterization and Phase 1 Trial Results of INBRX-109 in Chondrosarcoma
Year: 2023
Study Type: Preclinical and Phase 1 Clinical Trial
Drug: INBRX-109
Disease Focus: Chondrosarcoma
Trial Identifier: NCT03715933
Pharmacokinetic Data: Included
Population Characteristics: Adult patients, predominantly male and White
Endpoints: Safety, pharmacokinetics, immunogenicity
Supplementary Data: Tables S1-S3, Figures S1-S6
References: 1-11
Client Information Sheet: Call for cases: Dogs with osteosarcoma
Year: Not specified
Region / city: Not specified
Subject: Veterinary oncology, osteosarcoma in dogs
Document type: Research study invitation
Institution: Not specified
Author: Not specified
Target audience: Pet owners of dogs diagnosed with osteosarcoma
Period of validity: Not specified
Approval date: Not specified
Date of amendments: Not specified
Sulforhodamine B Assay and Cell Line Studies on CR-1-31B in Osteosarcoma Models
Year: 2023
Region / City: N/A
Theme: Cytotoxicity assays, cancer research
Document Type: Research Methodology
Organization / Institution: N/A
Author: Vichai et al., Ianevski et al., Duivenvoorden et al.
Target Audience: Researchers in oncology and pharmacology
Period of Action: N/A
Date of Approval: N/A
Date of Changes: N/A
Topics: Sarcomas Chondrosarcoma osteosarcoma